Loading...
  • Eye Institute, Al. Niepodległości 18, 02-653 Warsaw, Poland
  • Mon to Fri - 8:00 am to 8:00 pm, Sat Fri - 8:00 am to 4:00 pm

Oops...
No slides found, please add some slides

Retina

A NEW HOPE FOR AMD PATIENTS

Retinal Rejuvenation Therapy —
first non-invasive treatment for Age Related Macular Degeneration

Age-Related Macular Degeneration

What AMD is ?

Age-related macular degeneration is an eye disease that usually develops in people aged 50 years and older. It is clinically recognisable as a collection of ocular findings that can progressively lead to blindness. Early signs of age-related macular degeneration (eAMD) such as drusen and pigmentary abnormalities can be diagnosed through a simple eye examination, often years before sight threatening complications occur.

AMD is the leading cause of blindness in the developed world. In Europe, 50% of all blindness is caused by AMD.

 

It is estimated that AMD currently affects around 34 million people in the European Union (EU) and 22 million people in the five most populous European countries alone: Germany, France, the United Kingdom (UK), Italy and Spain. The number of patients affected by AMD in the EU is expected to rise by almost 25% based on population growth and ageing until 2050.

*Retinal Diseases in Europe, 2017

Age-Related Macular Degeneration

Who is at risk?

Age is a major risk factor for AMD. The disease is most likely to occur after age 60, but it can occur earlier.

Other risk factors for AMD include:

• Family history . People with a family history of AMD are at higher risk
• Smoking . Research shows that smoking doubles the risk of AMD
• Race. AMD is more common among Caucasians than among African-Americans or Hispanics/ Latinos.

If you are over the age of 50 and you have family history of AMD we highly recommend you visit your local eye care professional for an eye examination.

AMD

Symptoms of Age-Related Macular Degeneration

For the most part, age-related macular degeneration does not present any symptoms in the early stages; the disease is painless. However, patients may notice shadowy figures or blind spots in their central vision. It’s also not uncommon for lines to appear warped or wavy.

REVOLUTIONARY TECHNOLOGY

First Effective Therapy for patients with early stages of AMD

Revolutionary Treatment

What 2RT is?

Also known as Retinal Rejuvenation Therapy, 2RT is a non-invasive, pain-free procedure that stimulates a natural, biological healing response in the eye to intervene with early stages age-related macular degeneration. It is performed in your ophthalmologist’s office and typically takes no more than 10 minutes.

Non-invasive laser

How does 2RT work?

2RT applies nanosecond pulses of low-energy light to areas of the maximal retinal thickening (macular edema), stimulating a process of cellular rejuvenation. This process reduces drusen in the majority of treated eyes, demonstrating a partial reversal of the degenerative processes which cause AMD.

Interview

Retinal Rejuvenation

At the Inaugural European Laser Innovations Forum in Nice, Prof. John Marshall discussed the evolution of 2RT Retinal Rejuvenation Therapy as an intervention for early AMD – and how 2RT technology compares to other laser-based retinal treatments.

GET APPOINTMENT

Eye Institute in Warsaw has performed over 3000 2RT procedures . Get a Consultation Right Now! Call: +48 501 066 733

Appointment

Wet AMD happens when there is abnormal growth of and leakage from blood vessels under the macula, hence the disease being called “Wet” AMD. The leaking blood and fluid damages and scars the macula, which can affect your vision.

WET AMD

Intravitreal injections of anti-VEGF agents for wet Age Related Macular Degeneration

A method of treating exudative AMD is administering to the vitreous drugs that inhibit formation of pathological blood vessels. Such therapy primarily aims at inhibiting disease progress.

The treatment usually involves several injections, which are applied from time to time. A number of injections and time intervals between subsequent injections is determined by the ophthalmologist, based on the results of fluorescein angiography, OCT and other diagnostic examinations.

Intravitreal injections of anti-VEGF agents (Elyea, Lucentis) are used in case of retinal diseases, particularly in an exudate type of Age-related Macular Degeneration (AMD), diabetic retinopathy, high myopia, and retinal vein occlusion.

VEGF is a growth factor of abnormal blood vessels. In eyes which suffer from macular degeneration, its level is too high. Anti-VEGF agents block the VEGF factor permanently.

The intraocular injection is performed in the Eye Institute as a “walk-in, walk-out” outpatient procedure, in the treatment room. The procedure is performed by an ophthalmologist – a highly experienced specialist assisted by a nurse.

Risk factors for Wet AMD:

  • Dry AMD
  • Age 50 years or older
  • Family history of Wet AMD
  • Female Gender
  • Obesity
  • Caucasian Race
  • Smoking

How does wet AMD affect vision?

Common symptoms include blurriness in the center of your vision, blind spots or patches, straight lines that look wavy, or colors that look dull or washed out. In addition, objects may seem farther away than they really are. These symptoms may affect your ability to read, write, drive, and recognize faces.